PRR11 and cancer: Above all, EMT, PI3K/AKT/mTOR, Wnt/β-catenin signalings and biological molecules, including MMP2, TIMP-2, p21, p27, CDK2, cyclin A2, CTHRC1, LXN, EGR1, UCHL1, SNAT1 and PTTG1, have been testified to participate in the functional processes of PRR11, which might be feasible approaches for the targeted therapy of PRR11 in human cancers (Figure 2).